ENVVENO MEDICAL CORP (NVNO) Stock Price & Overview

NASDAQ:NVNOUS29415J2050

Current stock price

10.61 USD
-0.4 (-3.63%)
Last:

The current stock price of NVNO is 10.61 USD. Today NVNO is down by -3.63%. In the past month the price increased by 15.45%. In the past year, price decreased by -89.58%.

NVNO Key Statistics

52-Week Range8.67 - 196.7
Current NVNO stock price positioned within its 52-week range.
1-Month Range8.67 - 12.85
Current NVNO stock price positioned within its 1-month range.
Market Cap
7.003M
P/E
N/A
Fwd P/E
N/A
EPS (TTM)
-20.12
Dividend Yield
N/A

NVNO Stock Performance

Today
-3.63%
1 Week
-7.43%
1 Month
+15.45%
3 Months
-7.38%
Longer-term
6 Months -61.21%
1 Year -89.58%
2 Years -94.43%
3 Years -93.52%
5 Years N/A
10 Years N/A

NVNO Stock Chart

ENVVENO MEDICAL CORP / NVNO Daily stock chart

NVNO Technical Analysis

ChartMill assigns a technical rating of 2 / 10 to NVNO. When comparing the yearly performance of all stocks, NVNO is a bad performer in the overall market: 94.03% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

NVNO Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to NVNO. No worries on liquidiy or solvency for NVNO as it has an excellent financial health rating, but there are worries on the profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

NVNO Earnings

Next Earnings DateApr 28, 2026
Last Earnings DateFeb 27, 2026
PeriodQ3 / 2025
EPS Reported-$8.05
Revenue Reported
EPS Surprise 24.84%
Revenue Surprise %

NVNO Forecast & Estimates


Analysts
Analysts43.33
Price TargetN/A
EPS Next Y13.26%
Revenue Next YearN/A

NVNO Groups

Sector & Classification

NVNO Financial Highlights

Over the last trailing twelve months NVNO reported a non-GAAP Earnings per Share(EPS) of -20.12. The EPS decreased by -1412.78% compared to the year before.


Income Statements
Revenue(TTM)N/A
Net Income(TTM)-21.96M
Industry RankSector Rank
PM (TTM) N/A
ROA -67.89%
ROE -74.59%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%-2200%
Sales Q2Q%N/A
EPS 1Y (TTM)-1412.78%
Revenue 1Y (TTM)N/A

NVNO Ownership

Ownership
Inst Owners20.99%
Shares660.00K
Float510.00K
Ins Owners11.47%
Short Float %N/A
Short Ratio0.32

NVNO Competitors/Peers

The largest stocks on the US markets in the "Health Care Equipment" sub-industry
Full List
SymbolCompany NameTechnical RatingFundamental RatingFPEMarket Cap
ABT ABBOTT LABORATORIES18.81187.722B
ISRG INTUITIVE SURGICAL INC46.2167.678B
SYK STRYKER CORP22.27128.879B
BSX BOSTON SCIENTIFIC CORP19.77102.581B
EW EDWARDS LIFESCIENCES CORP27.1547.515B
IDXX IDEXX LABORATORIES INC38.7145.688B
BDX BECTON DICKINSON AND CO11.6945.376B
RMD RESMED INC18.833.629B
GEHC GE HEALTHCARE TECHNOLOGY13.6932.253B
DXCM DEXCOM INC25.2724.723B
ZBH ZIMMER BIOMET HOLDINGS INC10.9918.235B
HOLX HOLOGIC INC15.316.77B
PODD INSULET CORP3415.477B

About NVNO

Company Profile

NVNO logo image enVVeno Medical Corp. is a development stage medical device company, which develops tissue based solutions that are designed to be life sustaining or life enhancing for patients with cardiovascular disease, and peripheral arterial and venous disease. The company is headquartered in Irvine, California and currently employs 37 full-time employees. The company went IPO on 2018-05-31. The firm is focused on the advancement of bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of venous disease. The firm is developing surgical and non-surgical replacement venous valves for patients suffering from severe chronic venous insufficiency (CVI) of the deep venous system of the leg. The Company’s lead product is the VenoValve, which is a surgical replacement venous valve that is being evaluated in a U.S. pivotal study. The VenoValve is implanted into the femoral vein of the patient in an open surgical procedure via a 5-to-6-inch incision in the upper thigh. The firm is also developing a second product called enVVe, which is a non-surgical, transcatheter-based replacement venous valve. Both the VenoValve and enVVe are designed to act as one-way valves, to help assist in propelling blood up the veins of the leg, and back to the heart and lungs.

Company Info

IPO: 2018-05-31

ENVVENO MEDICAL CORP

70 Doppler

Irvine CALIFORNIA US

CEO: Robert Berman

Employees: 37

NVNO Company Website

NVNO Investor Relations

Phone: 19492612900

ENVVENO MEDICAL CORP / NVNO FAQ

Can you describe the business of ENVVENO MEDICAL CORP?

enVVeno Medical Corp. is a development stage medical device company, which develops tissue based solutions that are designed to be life sustaining or life enhancing for patients with cardiovascular disease, and peripheral arterial and venous disease. The company is headquartered in Irvine, California and currently employs 37 full-time employees. The company went IPO on 2018-05-31. The firm is focused on the advancement of bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of venous disease. The firm is developing surgical and non-surgical replacement venous valves for patients suffering from severe chronic venous insufficiency (CVI) of the deep venous system of the leg. The Company’s lead product is the VenoValve, which is a surgical replacement venous valve that is being evaluated in a U.S. pivotal study. The VenoValve is implanted into the femoral vein of the patient in an open surgical procedure via a 5-to-6-inch incision in the upper thigh. The firm is also developing a second product called enVVe, which is a non-surgical, transcatheter-based replacement venous valve. Both the VenoValve and enVVe are designed to act as one-way valves, to help assist in propelling blood up the veins of the leg, and back to the heart and lungs.


What is the current price of NVNO stock?

The current stock price of NVNO is 10.61 USD. The price decreased by -3.63% in the last trading session.


Does ENVVENO MEDICAL CORP pay dividends?

NVNO does not pay a dividend.


What is the ChartMill rating of ENVVENO MEDICAL CORP stock?

NVNO has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 2 out of 10.


Which stock exchange lists NVNO stock?

NVNO stock is listed on the Nasdaq exchange.


Would investing in ENVVENO MEDICAL CORP be a good decision?

This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on NVNO.


Can you provide the ownership details for NVNO stock?

You can find the ownership structure of ENVVENO MEDICAL CORP (NVNO) on the Ownership tab.